 "pharmaceuticals")
The return on capital employed (RoCE) of Indian drug makers has come down over the last five years because of higher investments in research and development (R&D) of new and complex generics, and quality compliance, data shows.
The trend is unlikely to reverse in the near term, say experts. The RoCE, a key metric that measures how well a company is generating profits from its capital, of top Indian drug makers has seen a decline between FY13-14 and FY18-19, shows data analysed by India Infoline (IIFL).
For Lupin, for example, it has come down to 9.5 per cent
The trend is unlikely to reverse in the near term, say experts. The RoCE, a key metric that measures how well a company is generating profits from its capital, of top Indian drug makers has seen a decline between FY13-14 and FY18-19, shows data analysed by India Infoline (IIFL).
For Lupin, for example, it has come down to 9.5 per cent
